Catalyst Pharmaceuticals currently holds a Zacks Rank #1 (Strong Buy). Consensus estimates for its current fiscal year call for earnings of $2.82 per share, up $0.29 over the past week, and revenues of $630.3 million, representing a 7% year-over-year increase.

The company has beaten earnings estimates in each of the trailing four quarters, delivering an average surprise of 35.2%, underscoring its consistent outperformance relative to analyst forecasts.